Vandetanib
- TRADE NAME: Caprelsa (AstraZeneca)
- INDICATIONS: Medullary thyroid cancer
- CLASS: Angiogenesis inhibitor / antiangiogenic agent, Epidermal growth factor receptor (EGFR) inhibitor / antagonist, Tyrosine kinase inhibitor
- HALF-LIFE: 19 days
Amiodarone, Amoxapine, Antiarrhythmics, Arsenic, Carbamazepine, Chloroquine, Clarithromycin, CYP3A4 inducers, Dexamethasone, Disopyramide, Dofetilide, Dolasetron, Efavirenz, Granisetron, Haloperidol, Methadone, Moxifloxacin, Pazopanib, Phenobarbital, Phenytoin, Pimozide, Procainamide, QT prolonging agents, Rifabutin, Rifampin, Rifapentine, Sotalol, St John's Wort, Telavancin
PREGNANCY CATEGORY: D
Contra-indicated in patients with congenital long QT syndrome.
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of vandetanib in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 01/31/2024
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric